The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements

[1]  M. Ebbo,et al.  Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. , 2022, Autoimmunity reviews.

[2]  F. Cacciapaglia,et al.  Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups , 2021, Journal of Autoimmunity.

[3]  S. Treon,et al.  Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia , 2021, Leukemia.

[4]  J. Curtis,et al.  Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.

[5]  S. Treon,et al.  How to Sequence Therapies in Waldenström Macroglobulinemia , 2021, Current Treatment Options in Oncology.

[6]  M. Kersten,et al.  Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. , 2021, Blood advances.

[7]  G. Alessio,et al.  The Spectrum of Ocular Manifestations in Patients with Waldenström’s Macroglobulinemia , 2021, Ocular immunology and inflammation.

[8]  N. Sharma,et al.  Advances in treatment and prevention of hepatitis B , 2021, World journal of gastrointestinal pharmacology and therapeutics.

[9]  M. Dimopoulos,et al.  Ibrutinib plus rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia: a safety evaluation , 2021, Expert opinion on drug safety.

[10]  H. Tomita,et al.  Virus-Driven Carcinogenesis , 2021, Cancers.

[11]  L. Quartuccio,et al.  Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis. , 2021, Clinical and experimental rheumatology.

[12]  H. Goldschmidt,et al.  Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. , 2021, The Lancet. Oncology.

[13]  L. Lojo,et al.  Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases , 2021, Vaccines.

[14]  A. Palumbo,et al.  Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life , 2021, Blood Cancer Journal.

[15]  G. Leroux,et al.  Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study. , 2020, Journal of autoimmunity.

[16]  S. Baldovino,et al.  Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls, and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. , 2020, Minerva medica.

[17]  M. Manns,et al.  Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R) , 2020, Zeitschrift für Gastroenterologie.

[18]  J. Pawlotsky,et al.  EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.

[19]  V. Gattei,et al.  Direct‐acting antiviral agents for hepatitis C virus‐mixed cryoglobulinaemia: dissociated virological and haematological responses , 2020, British journal of haematology.

[20]  D. Fotiadis,et al.  Cryoglobulinemic vasculitis in primary Sjögren's Syndrome: Clinical presentation, association with lymphoma and comparison with Hepatitis C-related disease. , 2020, Seminars in arthritis and rheumatism.

[21]  G. Lauletta,et al.  Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar) , 2020, Internal and Emergency Medicine.

[22]  L. Biard,et al.  Cryoglobulinemia after the era of chronic hepatitis C infection. , 2020, Seminars in arthritis and rheumatism.

[23]  X. Mariette,et al.  Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone , 2020, Annals of the Rheumatic Diseases.

[24]  S. Treon,et al.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Asch,et al.  Long‐Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents , 2020, Hepatology.

[26]  R. Bruno,et al.  Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection , 2019, Leukemia.

[27]  M. Dougados,et al.  2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2019, Annals of the rheumatic diseases.

[28]  M. Persico,et al.  Hepatitis C virus infection and non‐hepatocellular malignancies in the DAA era: A systematic review and meta‐analysis , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[29]  P. Sarzi-Puttini,et al.  Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. , 2019, Autoimmunity reviews.

[30]  H. El‐Serag,et al.  The effects of sustained virological response to direct‐acting anti‐viral therapy on the risk of extrahepatic manifestations of hepatitis C infection , 2019, Alimentary pharmacology & therapeutics.

[31]  A. Zignego,et al.  Long‐lasting persistence of large B‐cell clones in hepatitis C virus‐cured patients with complete response of mixed cryoglobulinaemia vasculitis , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[32]  D. Thabut,et al.  Long‐term Efficacy of Interferon‐Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[33]  M. Sise,et al.  The association of hepatitis C infection with the onset of CKD and progression into ESRD , 2018, Seminars in dialysis.

[34]  S. Russi,et al.  Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis , 2018, Clinical and Experimental Medicine.

[35]  D. Roccatello,et al.  Cryoglobulinaemia , 2018, Nature Reviews Disease Primers.

[36]  X. Forns,et al.  Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. , 2018, Gastroenterology.

[37]  E. Ledent,et al.  Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention , 2018, Expert review of vaccines.

[38]  D. Vergani,et al.  Interferon‐free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis , 2018, Alimentary pharmacology & therapeutics.

[39]  A. Riva,et al.  Apheresis treatment of cryoglobulinemic vasculitis: A multicentre cohort study of 159 patients. , 2018, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[40]  S. Antinori,et al.  Direct-Acting Antivirals and Mixed Cryoglobulinemia Vasculitis: Long-Term Outcome of Patients Achieving HCV Eradication , 2017, The American Journal of Gastroenterology.

[41]  S. Pol,et al.  Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment , 2017, The New England journal of medicine.

[42]  M. Kowgier,et al.  Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia , 2017, The American Journal of Gastroenterology.

[43]  D. Dingli,et al.  Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia , 2017, American journal of hematology.

[44]  S. Pol,et al.  Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. , 2017, Gastroenterology.

[45]  J. Kramer,et al.  The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection , 2017, Gut.

[46]  A. Mangia,et al.  Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. , 2017, Journal of hepatology.

[47]  M. Murad,et al.  Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation? , 2017, Gastroenterology report.

[48]  M. Ghany.  Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. , 2017, Best practice & research. Clinical gastroenterology.

[49]  A. Mangia,et al.  International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. , 2017, Autoimmunity reviews.

[50]  S. Russi,et al.  Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience , 2017, Arthritis Research & Therapy.

[51]  X. Forns,et al.  Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus–Associated Cryoglobulinemia Treated With Direct‐Acting Antivirals , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[52]  A. Gabrielli,et al.  HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC). , 2017, Clinical and experimental rheumatology.

[53]  M. Gertz,et al.  How I treat cryoglobulinemia. , 2017, Blood.

[54]  A. Mangia,et al.  International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. , 2016, Autoimmunity reviews.

[55]  R. Bruno,et al.  Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. , 2016, Blood.

[56]  L. Petraccia,et al.  Prospective study of guideline‐tailored therapy with direct‐acting antivirals for hepatitis C virus‐associated mixed cryoglobulinemia , 2016, Hepatology.

[57]  S. Pol,et al.  Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. , 2016, Annals of the rheumatic diseases.

[58]  S. Treon,et al.  Rituximab intolerance in patients with Waldenström macroglobulinaemia , 2016, British journal of haematology.

[59]  L. Dal Maso,et al.  Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[60]  N. Dunbar,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue , 2016, Journal of clinical apheresis.

[61]  R. Chung,et al.  Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents , 2016, Hepatology.

[62]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[63]  T. Berg,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.

[64]  X. Mariette,et al.  Non HCV-related infectious cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey and systematic review of the literature. , 2015, Journal of autoimmunity.

[65]  T. Hassanein,et al.  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study , 2015, The Lancet.

[66]  D. Lipsker,et al.  Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases , 2015, British journal of haematology.

[67]  S. Treon,et al.  The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. , 2014, Blood.

[68]  D. Sansonno,et al.  Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. , 2013, The New England journal of medicine.

[69]  V. Conteduca,et al.  Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection , 2013, Medicine.

[70]  M. Hansmann,et al.  Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. , 2013, Journal of hepatology.

[71]  J. Murray,et al.  Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. , 2013, Gastroenterology.

[72]  X. Mariette,et al.  The Spectrum of Type I Cryoglobulinemia Vasculitis , 2013, Medicine.

[73]  M. Manns,et al.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.

[74]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[75]  F. Carrat,et al.  Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. , 2012, Blood.

[76]  A. Gabrielli,et al.  A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. , 2012, Arthritis and rheumatism.

[77]  Zonghui Hu,et al.  A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. , 2012, Arthritis and rheumatism.

[78]  D. Roccatello,et al.  Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. , 2011, Autoimmunity reviews.

[79]  C. Tinelli,et al.  A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. , 2011, Autoimmunity reviews.

[80]  R. Bruno,et al.  Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. , 2011, Autoimmunity reviews.

[81]  F. Breedveld,et al.  Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis , 2011, Annals of the Rheumatic Diseases.

[82]  J. Piette,et al.  Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. , 2010, Blood.

[83]  P. Romagnoli,et al.  Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. , 2010, Blood.

[84]  Felicia A Tucci,et al.  Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. , 2010, Blood.

[85]  Z. Amoura,et al.  Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. , 2009, Arthritis and rheumatism.

[86]  V. Tesar,et al.  Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis , 2009, Annals of Internal Medicine.

[87]  D. Landau,et al.  The B lymphocyte stimulator receptor–ligand system in hepatitis C virus-induced B cell clonal disorders , 2008, Annals of the rheumatic diseases.

[88]  J. Cerhan,et al.  Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[89]  S. Frost,et al.  Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. , 2007, Blood.

[90]  J. Piette,et al.  Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. , 2006, Archives of internal medicine.

[91]  G. Panayiotakopoulos,et al.  Decreased prevalence of mixed cryoglobulinemia in the HAART era among HIV‐positive, HCV‐negative patients , 2006, Journal of medical virology.

[92]  D. Sansonno,et al.  Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. , 2005, The Lancet. Infectious diseases.

[93]  Felicia A Tucci,et al.  Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. , 2003, Blood.

[94]  X. Mariette,et al.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. , 2002, The New England journal of medicine.

[95]  J. Yagüe,et al.  Cryoglobulinemia: Study of Etiologic Factors and Clinical and Immunologic Features in 443 Patients from a Single Center , 2001, Medicine.

[96]  D. Sansonno,et al.  Hepatitis C virus infection, mixed cryoglobulinemia, and non-Hodgkin's lymphoma: an emerging picture. , 1998, Leukemia & lymphoma.

[97]  R. Chung,et al.  A role for hepatitis C virus infection in type II cryoglobulinemia. , 1992, The New England journal of medicine.

[98]  D. Sansonno,et al.  Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia , 1992, Clinical and experimental immunology.

[99]  G. Pasero,et al.  Antibodies against hepatitis C virus in mixed cryoglobulinemia patients , 1991, Infection.

[100]  J. Clauvel,et al.  Biologic and clinical significance of cryoglobulins. A report of 86 cases. , 1974, The American journal of medicine.

[101]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[102]  M. Meltzer,et al.  Cryoglobulinemia--a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. , 1966, The American journal of medicine.

[103]  A. Lerner,et al.  STUDIES OF CRYOGLOBULINS. I. UNUSUAL PURPURA ASSOCIATED WITH THE PRESENCE OF A HIGH CONCENTRATION OF CRYOGLOBULIN (COLD PRECIPITABLE SERUM GLOBULIN) , 1947, The American journal of the medical sciences.

[104]  N. Sharma,et al.  Advances in treatment and prevention of hepatitis B , 2021, World journal of gastrointestinal pharmacology and therapeutics.

[105]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[106]  C. Kallenberg,et al.  Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. , 2010, Arthritis and rheumatism.